

## Disclosures

### Personal Commercial (13)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
AbbVie, Inc.	Data Safety Monitoring Board	Significant (>= \$5,000)	<a href="#">General Cardiology</a>
Amgen	Data Safety Monitoring Board	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Boeringer Ingelheim	Data Safety Monitoring Board	Significant (>= \$5,000)	<a href="#">Acute Coronary Syndromes</a>
Cleveland Heart Labs	Research/Research Grants ‡ CASABLANCA	Significant (>= \$5,000)	<a href="#">Acute Coronary Syndromes</a> <a href="#">Stable Ischemic Heart Disease</a>
Critical Diagnostics	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Janssen Pharmaceuticals, Inc	Data Safety Monitoring Board	Significant (>= \$5,000)	<a href="#">Prevention</a>
Novartis	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Phillips	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a>
Prevenio	Research/Research Grants ‡ CASABLANCA substudy	Significant (>= \$5,000)	<a href="#">Prevention</a>
Roche Diagnostics	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Heart Failure and Cardiomyopathies</a> <a href="#">General Cardiology</a>
Siemens	Data Safety Monitoring Board	Significant (>= \$5,000)	<a href="#">Acute Coronary Syndromes</a>
Singulex	Research/Research Grants ‡ CASABLANCA	Significant (>= \$5,000)	<a href="#">Acute Coronary Syndromes</a> <a href="#">Heart Failure and Cardiomyopathies</a>

### Personal Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 4/3/2018

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 4/3/2018

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 4/3/2018

---

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.